At AACR, researchers reported clinical value for tumor-informed MRD detection using whole-genome sequencing paired with Ultima Genomics duplex sequencing in TRACERx. The approach, using paired plus-minus sequencing (ppmSeq), enabled intermediate risk group identification without bespoke assays, with ctDNA analyses showing concordance with prior datasets and relapse-free survival prediction.